Pub. Date : 2013 May
PMID : 23468082
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
1 | Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. | ponatinib | mechanistic target of rapamycin kinase | Homo sapiens |
2 | CONCLUSIONS: These encouraging preclinical findings suggest the inhibition of both FGFR2 and mTOR by the ponatinib-ridaforolimus combination may provide a new therapeutic strategy to treat advanced endometrial cancers with dual pathway dysregulation. | ponatinib | mechanistic target of rapamycin kinase | Homo sapiens |